The Stability Trade-Off at the Heart of ASD Formulation
The physicochemical advantage of an amorphous solid dispersion is real and well-documented. By eliminating the crystal lattice energy barrier, amorphous forms dissolve faster and achieve higher apparent solubility in biological fluids. For BCS Class II molecules with poor oral bioavailability, this translates directly into better clinical performance.
But amorphous forms pay for that advantage with thermodynamic instability. An amorphous solid is at a higher energy state than its crystalline counterpart. Given sufficient molecular mobility, the amorphous drug will tend to return to the crystalline state, losing the solubility advantage that made the formulation worthwhile. Managing this tendency, across the manufacturing process, the packaging, and the intended shelf life, is the central stability challenge of ASD development.
The Physics of Recrystallisation
Glass Transition Temperature (Tg)
The glass transition temperature is the single most important physical parameter for understanding the stability of an amorphous solid. Below the Tg, molecular mobility in the amorphous matrix is very low, and recrystallisation is kinetically inhibited. Above the Tg, mobility increases substantially, and the rate of crystallisation increases rapidly. For practical storage stability, the Tg of the amorphous drug or ASD should be significantly above the intended storage temperature. A rule of thumb used in the field is that the Tg should be at least 50 degrees Celsius above the storage temperature, though this is a guideline rather than a regulatory requirement.
The Effect of Moisture
Water acts as a plasticiser for amorphous solids, reducing the Tg and increasing molecular mobility. An amorphous drug that is stable under dry conditions may crystallise rapidly when exposed to elevated humidity. This makes moisture control during manufacturing and packaging critical. It also means that ICH stability studies at 75% relative humidity are a particularly challenging condition for amorphous formulations and an important test of the robustness of the stabilisation strategy.
Drug-Polymer Miscibility
In an amorphous solid dispersion, the drug must remain miscible with the polymer matrix throughout its shelf life. Phase separation, where the drug migrates out of the polymer matrix into drug-rich domains, accelerates recrystallisation. Drug-polymer miscibility is assessed using techniques including modulated DSC, solid-state NMR, and computational solubility parameter calculations during formulation development.
Stability Risk Assessment Framework
| Risk Factor | Low Risk Indicator | High Risk Indicator | Mitigation |
| Tg of ASD | Greater than 80 degrees C at ICH storage conditions | Below 60 degrees C | Increase polymer content; use higher-Tg polymer |
| Moisture sensitivity | Tg reduction less than 10 degrees C at 75% RH | Tg reduction greater than 20 degrees C | Moisture-barrier packaging; desiccant; enteric coating |
| Drug-polymer miscibility | Single Tg observed; no phase separation by DSC | Two Tg events or crystalline peaks in XRPD | Reformulate with more compatible polymer |
| Recrystallisation tendency | No XRPD peaks after 6 months at 40 degrees C/75% RH | XRPD peaks within 1-3 months | Increase polymer ratio; add crystallisation inhibitor |
| Drug loading | Below 30% w/w | Above 50% w/w | Evaluate lower drug loading; consider alternative polymer |
The thresholds above represent general guidance based on published ASD development literature and are not regulatory requirements. Programme-specific assessment is always required.
Analytical Tools for Monitoring Amorphous Stability
A stability monitoring programme for an ASD must be able to detect early-stage recrystallisation before it becomes analytically visible by standard release methods. The analytical toolkit for amorphous stability monitoring includes XRPD for detecting crystalline conversion, modulated DSC for measuring Tg and detecting phase separation, and dissolution testing using biorelevant media to capture changes in in vitro performance. Raman spectroscopy and solid-state NMR offer additional sensitivity for detecting early molecular-level changes.
How Ardena Manages ASD Stability
Ardena’s formulation teams at Somerset and Pamplona design ASD stability programmes that integrate physical stability monitoring with dissolution performance assessment from the earliest development batches. Stability studies are structured to generate data that supports regulatory filings under ICH Q1A(R2), with additional stress conditions designed to probe the specific failure modes relevant to the formulation.
The solid state research team in Ghent provides the advanced characterisation capabilities needed to understand drug-polymer interactions and phase behaviour, feeding data into the formulation decisions made at Somerset and Pamplona in a coordinated way.
